Rewire Weekly is one science backed protocol every Tuesday, drawn from the latest longevity and neuroscience research. I am a practitioner and researcher. The goal is not wellness content. It is clinical evidence translated into something you can actually use.
If you have eaten pomegranates in the last year and assumed the health benefits were working as advertised, the mechanism you were banking on may not have been firing.
Urolithin A is not in pomegranates. It is produced by gut bacteria that convert ellagitannins from pomegranates, strawberries, and walnuts into urolithin A inside your colon. Whether that conversion happens depends entirely on which gut bacteria you carry. Roughly 60 to 70 percent of adults do not have the microbial profile needed to produce meaningful amounts from food. They fall into metabotype B (partial producers) or metabotype 0 (non-producers). Even metabotype A individuals, the 30 to 40 percent who convert ellagitannins efficiently, generate plasma concentrations significantly below the threshold associated with mitophagy activation in clinical trials.
This is the gap that supplemental urolithin A is built to close. It is also why this compound is unusual in the longevity space: the argument for supplementation is not that your diet is inadequate. It is that your gut biology probably cannot complete the conversion regardless of what you eat.
What urolithin A is actually doing at the cellular level
Mitochondria degrade over time. This is not a metaphor for aging — it is a literal accumulation of damaged organelles that can no longer generate ATP efficiently and that begin releasing reactive oxygen species into the surrounding cell. The clearance mechanism that should remove these organelles is called mitophagy: selective autophagy targeting mitochondria that have been marked for destruction.
The pathway urolithin A activates is PINK1/Parkin. In healthy mitochondria, the kinase PINK1 is rapidly imported into the inner membrane and degraded. In damaged mitochondria where the membrane potential has collapsed, PINK1 accumulates on the outer membrane, recruits Parkin (an E3 ubiquitin ligase), and tags the damaged organelle for engulfment by autophagosomes. Urolithin A sensitizes this pathway, upregulating the rate at which damaged mitochondria are tagged and cleared without requiring the cell to deteriorate to the point of spontaneous PINK1 accumulation.
The downstream consequence matters. When damaged mitochondria are cleared, the cell initiates mitochondrial biogenesis to replace them. The new mitochondria are more efficient. They produce less reactive oxygen species per unit of ATP. In muscle cells, this translates to lower acylcarnitine accumulation (a direct marker of incomplete fatty acid oxidation) and reduced systemic inflammatory signaling. In the brain, the same mechanism suppresses NLRP3 inflammasome activation in microglia, which reduces the production of IL-1 beta and TNF alpha — two of the primary cytokines that degrade neuronal function with age.
A secondary pathway runs through SIRT1. Urolithin A activates SIRT1 (a NAD+ dependent deacetylase) and suppresses mTOR, which together amplify the broader autophagic program. This is the same pathway activated by caloric restriction and fasting. Urolithin A appears to partially replicate that cellular effect without the metabolic stress.
What the human trials actually show
Two controlled trials define most of the human evidence, and both used Mitopure, the branded purified form of urolithin A manufactured by Timeline Nutrition.
Singh and colleagues (2022, Cell Reports Medicine, 202 citations) enrolled middle-aged adults in a four month randomized, placebo controlled trial of Mitopure at 500mg or 1000mg per day. The trial found approximately 12 percent improvement in muscle strength across both dose groups. Plasma acylcarnitines were significantly lower, indicating improved mitochondrial fatty acid oxidation efficiency. CRP was also significantly reduced. The primary endpoint, peak power output, was not significantly improved compared to placebo. This is worth stating clearly: the trial missed its primary endpoint while showing meaningful secondary effects on strength and biomarkers. The trial was led by Singh, who is employed by Timeline Nutrition. The effect is real, but the industry funding is a factor informed readers will note.
The independent replication comes from Liu and colleagues (2022, JAMA Network Open, 150 citations), a trial with no industry involvement. They enrolled 66 adults aged 65 to 90 years, giving 1000mg of urolithin A per day for four months in a double blind, placebo controlled design. Muscle endurance in both hand and leg muscles improved significantly at two months: the number of muscle contractions until fatigue increased substantially in the urolithin A group compared to placebo. Plasma acylcarnitines, ceramides, and CRP were all reduced. The six minute walk test showed 60.8 meters of improvement in the urolithin A group versus 42.5 meters in placebo, but this difference did not reach statistical significance. Maximal ATP production measured by MRS was also not significantly improved versus placebo.
A 2024 systematic review by Kuerec and colleagues (Ageing Research Reviews, 44 citations) synthesized five studies including 250 healthy individuals receiving 10 to 1000mg per day for 28 days to four months. Consistent findings across all studies: anti-inflammatory effect at higher doses, upregulated mitochondrial gene expression and autophagy markers, increased muscle strength and endurance. The review also confirmed that urolithin A did not affect mitochondrial maximal ATP production, biogenesis measures, cardiovascular outcomes, or gut microbiota composition. The honest read: the inflammation and mitochondrial biomarker effects are consistent across industry and independent trials. The ceiling is biomarkers and endurance, not peak metabolic output.
The brain case: mechanistically sound, not yet proven in humans
All of the cognitive and neuroprotection data on urolithin A is preclinical. I want to be explicit about that before going further.
Qiu and colleagues (2022, Neuropharmacology, 133 citations) showed that urolithin A reduced dopaminergic neuron loss, ameliorated behavioral deficits, and attenuated neuroinflammation in a Parkinson's disease mouse model. The mechanism was mitophagy specifically in microglia: urolithin A promoted mitophagic clearance in brain immune cells, which suppressed NLRP3 inflammasome activation and reduced the inflammatory cascade that degrades neurons. The researchers confirmed the mechanism was mitophagy-dependent by showing that pharmacological and genetic blockade of mitophagy eliminated the neuroprotective effect.
Chen and colleagues (2019, Neurotherapeutics, 173 citations) administered urolithin A to mice in a validated accelerated brain aging model for two months. Urolithin A significantly suppressed upregulation of miR-34a, which preserved SIRT1 signaling and allowed autophagy to continue clearing cellular debris. Cognitive impairment and apoptosis markers were both ameliorated.
These are mouse studies. The translational gap exists. What exists in humans is the downstream inflammatory biomarker signal. Every human trial showing CRP and acylcarnitine reductions is demonstrating that mitochondrial clearance is activating systemically. Whether that activation extends to neuronal tissue at the same magnitude is the question a 650-person brain health trial (currently underway as of 2026) is built to answer. Until those results are published, the brain case for urolithin A rests on mechanism and biomarker signal rather than cognitive outcome data. That is still a meaningful basis for a 40+ population thinking in terms of upstream mitochondrial maintenance rather than acute cognitive enhancement.
This week's protocol
The goal is systematic mitochondrial quality control: clearing degraded mitochondria, reducing systemic inflammation, and maintaining the mitochondrial substrate that neuronal energy production depends on as you age.
Dose: 500mg per day of urolithin A (as Mitopure). This is the minimum dose that activates mitophagic gene expression and reduces acylcarnitines in the Singh trial. If you are over 60 or managing measurable muscle decline, 1000mg per day is the dose used in the JAMA Network Open trial and produced the stronger muscle endurance signal at two months.
Timing: Morning, with breakfast. No circadian timing constraint applies here. Unlike phosphatidylserine, where morning dosing conflicts with the cortisol awakening response, urolithin A has no known interaction with diurnal hormone rhythms. Morning is primarily a compliance anchor.
Food: Take with a fat-containing meal. Urolithin A is fat soluble. Food with any fat source (eggs, avocado, olive oil) improves absorption. Taking it on an empty stomach reduces bioavailability.
Duration: Minimum two months before assessing results. Muscle endurance improvements in the JAMA Network Open trial were measurable at two months. Biomarker changes (acylcarnitines, CRP) require longer to stabilize. Do not assess at six weeks.
Tracking: Two options, in order of signal quality. First: CRP via standard bloodwork at baseline and four months. The target is CRP below 1.0 mg/L. The trials saw significant reductions from this biomarker consistently. Second: a grip endurance test at baseline and two months. Time how long you can maintain a sustained squeeze at 50 percent of your max grip. These are the exact endpoints the clinical trials measured.
Note on combination: Urolithin A and NMN or NR are mechanistically additive. NAD+ precursors support mitochondrial biogenesis via SIRT1 activation. Urolithin A clears damaged mitochondria via mitophagy. The two pathways are complementary, not redundant: one removes the damaged, the other fuels the new. If you are running an NAD+ precursor from the Rewire stack, maintaining that protocol alongside urolithin A is supported by the mechanistic logic. Take them at the same time with the same meal.
This week's tools
Urolithin A (as Mitopure, 500mg or 1000mg per day) — The only form of urolithin A with positive RCT data is Mitopure, the branded ingredient used in both the Cell Reports Medicine and JAMA Network Open trials. Generic urolithin A products have not been validated in human trials. Look for "Urolithin A as Mitopure" on the label. Confirm third party identity testing. The minimum threshold dose is 500mg per day; 1000mg per day is the dose used in the older adult trial with the stronger endurance signal.
I have reviewed the available options against the clinical evidence and the most reliably standardized forms are available through my Fullscript dispensary at a discount below retail. Urolithin A is included alongside the full cognitive and longevity stack I use and recommend.
If this issue was useful, forward it to one colleague who tracks their health seriously. That is the most direct way to help this newsletter grow.
Have a question about the research or a specific stack you want me to look at? Reply to this email. I read every response.